The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta...

The drug is approved for treating both early and late stage or metastatic HER2-positive breast cancer.

PHESGO was first approved by the US FDA in June 2020 during the peak of the Covid pandemic, by the European Medicines Agency (EMA) in Decem...

These drugs will attack cancer cells in the body without damaging surrounding healthy ones.

Buy Biocon Ltd. at a price target of Rs 560.

It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.

Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectiv...

Roche Products (India) Private Ltd is a wholly owned subsidiary of the Switzerland based Roche Group and has products in therapeutic areas .

India is a fragmented market and has its own challenges; there is a private sector and public sector. About 80% of the healthcare expenses ...

Roche said patients will be offered equated monthly instalment schemes for Perjeta and Kadcyla through financial institutions in the coming...